Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the compensation committee of the company's board of directors granted thirteen new employees options to purchase a total of 28,900 shares of the company's common stock at an exercise price per share of $33.70, which was the closing price on april 8, 2022, and restricted stock units to acquire a total of 14,45
RCUS Ratings Summary
RCUS Quant Ranking